Histone Deacetylases Enzyme, Copper, and IL-8 Levels in Patients with Alzheimer's Disease

Overview

Journal Am J Alzheimers Dis Other Demen

Publisher Sage Publications

Specialty Neurology

Date 2012 Dec 18

PMID 23242124

Citations 45

Authors

Mohamad A Alsadany

Hanan H Shehata

Magda I Mohamad

Riham G Mahfouz

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of cognitive abilities. Epigenetic modification, oxidative stress, and inflammation play an important role in the pathogenesis of the disease. We aimed to detect noninvasive peripheral biomarkers with a high degree of sensitivity and specificity in diagnosis and progression of AD.

Methods: A total of 25 elderly patients with AD and 25 healthy control participants were selected and subjected to cognitive assessment and laboratory measures including histone deacetylases (HDACs), copper, and interleukin 8 (IL-8) levels.

Results: The levels of HDACs, copper, and IL-8 were significantly higher in patients with AD (P < .001) and had a significant negative effect on all cognitive assessment tests. Receiver-operating curve (ROC) analysis revealed that HDACs and copper levels had higher sensitivity and specificity.

Conclusions: Plasma levels of HDACs and copper may be used as peripheral biomarkers in diagnosis of AD, while IL-8 level could be a useful biomarker in following AD progression.

Citing Articles

The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization.

Leisgang Osse A, Kinney J, Cummings J Alzheimers Dement (N Y). 2025; 11(1):e70050.

PMID: 39935614 PMC: 11812129. DOI: 10.1002/trc2.70050.

Brain interleukins and Alzheimer's disease.

Abdelhamed H, Hassan A, Sakraan A, Al-Deeb R, Mousa D, Aboul Ezz H Metab Brain Dis. 2025; 40(2):116.

PMID: 39891777 PMC: 11787210. DOI: 10.1007/s11011-025-01538-5.

Mitochondrial pathways of copper neurotoxicity: focus on mitochondrial dynamics and mitophagy.

Aschner M, Skalny A, Lu R, Martins A, Tizabi Y, Nekhoroshev S Front Mol Neurosci. 2024; 17:1504802.

PMID: 39703721 PMC: 11655512. DOI: 10.3389/fnmol.2024.1504802.

Role of Thrombosis in Neurodegenerative Diseases: An Intricate Mechanism of Neurovascular Complications.

Beura S, Panigrahi A, Yadav P, Kulkarni P, Lakhanpal V, Singh B Mol Neurobiol. 2024; 62(4):4802-4836.

PMID: 39482419 DOI: 10.1007/s12035-024-04589-4.

Variant-to-function mapping of late-onset Alzheimer's disease GWAS signals in human microglial cell models implicates at the locus.

Burton E, Argenziano M, Cook K, Ridler M, Lu S, Su C bioRxiv. 2024; .

PMID: 39229212 PMC: 11370593. DOI: 10.1101/2024.08.22.609230.

References

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Hack C, Hart M, van Schijndel R, Eerenberg A, Nuijens J, Thijs L . Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun. 1992; 60(7):2835-42. PMC: 257242. DOI: 10.1128/iai.60.7.2835-2842.1992. View

Qiu C, Kivipelto M, von Strauss E . Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009; 11(2):111-28. PMC: 3181909. View

Morris J . Clinical assessment of Alzheimer's disease. Neurology. 1997; 49(3 Suppl 3):S7-10. DOI: 10.1212/wnl.49.3_suppl_3.s7. View

Tuppo E, Arias H . The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2004; 37(2):289-305. DOI: 10.1016/j.biocel.2004.07.009. View

Boyum A . Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968; 97:77-89. View

Scarpa S, Cavallaro R, Danselmi F, Fuso A . Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J Alzheimers Dis. 2006; 9(4):407-14. DOI: 10.3233/jad-2006-9406. View

McAfoose J, Baune B . Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2008; 33(3):355-66. DOI: 10.1016/j.neubiorev.2008.10.005. View

Grammas P, Samany P, Thirumangalakudi L . Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis. 2006; 9(1):51-8. DOI: 10.3233/jad-2006-9105. View

10.

Zawia N, Lahiri D, Cardozo-Pelaez F . Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med. 2009; 46(9):1241-9. PMC: 2673453. DOI: 10.1016/j.freeradbiomed.2009.02.006. View

11.

ROSEN W, Mohs R, Davis K . A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141(11):1356-64. DOI: 10.1176/ajp.141.11.1356. View

12.

Abel T, Zukin R . Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008; 8(1):57-64. PMC: 2405764. DOI: 10.1016/j.coph.2007.12.002. View

13.

Welsh K, Butters N, Mohs R, Beekly D, Edland S, Fillenbaum G . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994; 44(4):609-14. DOI: 10.1212/wnl.44.4.609. View

14.

Soo Lee K, Chung J, Choi T, Suh S, Oh B, Hong C . Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 28(4):281-7. DOI: 10.1159/000245156. View

15.

Mattson M . Pathways towards and away from Alzheimer's disease. Nature. 2004; 430(7000):631-9. PMC: 3091392. DOI: 10.1038/nature02621. View

16.

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

17.

Atkinson R, Shiffrin R . The control of short-term memory. Sci Am. 1971; 225(2):82-90. DOI: 10.1038/scientificamerican0871-82. View

18.

Morris J, HEYMAN A, Mohs R, Hughes J, van Belle G, Fillenbaum G . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989; 39(9):1159-65. DOI: 10.1212/wnl.39.9.1159. View

19.

Squitti R, Pasqualetti P, Forno G, Moffa F, Cassetta E, Lupoi D . Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology. 2005; 64(6):1040-6. DOI: 10.1212/01.WNL.0000154531.79362.23. View

20.

Kim S, Song J, Kim S, Han C, Park M, Koh Y . Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol. 2011; 11:51. PMC: 3120663. DOI: 10.1186/1471-2377-11-51. View